Stock ENSC ENSYSCE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 29/06/2024 am IST 		5-day change 1st Jan Change
0.5065 USD -5.49% Intraday chart for Ensysce Biosciences, Inc. +1.28% -52.22%
28/05 Ensysce Biosciences Back in Compliance With Nasdaq MT
20/05 Sector Update: Health Care Stocks Softer Late Afternoon MT

Business Summary

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Number of employees: 7

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceuticals
100.0 %
3 100.0 % 2 100.0 % -11.61%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
3 100.0 % 2 100.0 % -11.61%

Managers

Managers TitleAgeSince
D. Kirkpatrick CEO
 Chief Executive Officer 67 01/09/01
David Humphrey DFI
 Director of Finance/CFO 55 01/21/01
Jeffrey Millard COO
 Chief Operating Officer 49 01/19/01
William K. Schmidt CTO
 Chief Tech/Sci/R&D Officer 74 01/16/01
Linda Pestano PRN
 Corporate Officer/Principal - 15/21/15
Geoffrey Birkett PRN
 Corporate Officer/Principal 61 -
Richard Wright PRN
 Corporate Officer/Principal - -
David Tanzer PRN
 Corporate Officer/Principal - 22/21/22

Members of the board

Members of the board TitleAgeSince
Steven Martin BRD
 Director/Board Member 63 01/20/01
D. Kirkpatrick CEO
 Chief Executive Officer 67 01/09/01
Bob Gower CHM
 Chairman 86 01/08/01
Lee Rauch BRD
 Director/Board Member - 08/22/08
William Chang BRD
 Director/Board Member 68 01/16/01
Andrew Benton BRD
 Director/Board Member 72 01/19/01
Adam Levin BRD
 Director/Board Member 45 01/21/01
Curtis Rosebraugh BRD
 Director/Board Member 66 01/21/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 7,585,253 7,410,498 ( 97.70 %) 81 ( 0.001068 %) 97.70 %

Shareholders

NameEquities%Valuation
Sabby Management LLC
3.040 %
230,554 3.040 % 132 569 $
Lincoln Park Capital LLC
1.635 %
124,008 1.635 % 71 305 $
Bob Gower
1.607 %
121,890 1.607 % 70 087 $
William Chang
0.4063 %
30,815 0.4063 % 17 719 $
Heights Capital Management, Inc.
0.3701 %
28,073 0.3701 % 16 142 $
Andrew Benton
0.2640 %
20,025 0.2640 % 11 514 $
Geode Capital Management LLC
0.2415 %
18,318 0.2415 % 10 533 $
Vanguard Group, Inc. (Subfiler)
0.2396 %
18,175 0.2396 % 10 451 $
UBS Securities LLC
0.1662 %
12,610 0.1662 % 7 251 $
Renaissance Technologies LLC
0.1391 %
10,554 0.1391 % 6 069 $

Company contact information

Ensysce Biosciences, Inc.

7946 Ivanhoe Avenue Suite 201

92037, La Jolla

+

http://www.ensysce.com
address Ensysce Biosciences, Inc.(ENSC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Ensysce Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENSYSCE BIOSCIENCES, INC. Stock Ensysce Biosciences, Inc.
-52.22% 38.42L
MODERNA, INC. Stock Moderna, Inc.
+19.41% 4.55TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 3.85TCr
LONZA GROUP AG Stock Lonza Group AG
+38.65% 3.81TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 3.07TCr
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 2.6TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 2.59TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 1.41TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 1.27TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 1.13TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ENSC Stock
  4. Company Ensysce Biosciences, Inc.